Sagimet Biosciences Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
-2.0%projected annual EPS growth
Analyst Coverage
10analysts covering
FY EPS (est.)
-$1.22next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 12 Nov 2026 |
| Q4 and Full Year 2026 Earnings Release | 11 Mar 2027 |
Monitoring Framework
Key Performance Indicators
Cash, Cash Equivalents, and Marketable Securities Quarterly104.5MTarget: Sufficient to fund operations through 2028
Quarterly Net Loss Quarterly-10.7MTarget: Tighter cost management and narrowed losses
Quarterly Research and Development (R&D) Expense Quarterly7MTarget: Optimized clinical trial spending
Watch Items
- Initiation of U.S. Phase 3 clinical trial of denifanstat for moderate to severe acneTrigger: IND clearance from the FDAAction: Advance denifanstat into a pivotal 800-patient trial in the second half of 2026
- Initiation of Phase 2 clinical trial of TVB-3567 for moderate to severe acneTrigger: Completion of Phase 1 clinical trial and regulatory consultationAction: Launch Phase 2 trial in the second half of 2026
- Initiation of Phase 2 proof-of-concept trial of denifanstat and resmetirom combination in F4 MASHTrigger: Securing non-dilutive financingAction: Advance combination therapy into Phase 2 clinical development in the second half of 2026
Research as of 20 Jun 2026